WO2011111072A9 - Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer - Google Patents

Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer Download PDF

Info

Publication number
WO2011111072A9
WO2011111072A9 PCT/IN2011/000161 IN2011000161W WO2011111072A9 WO 2011111072 A9 WO2011111072 A9 WO 2011111072A9 IN 2011000161 W IN2011000161 W IN 2011000161W WO 2011111072 A9 WO2011111072 A9 WO 2011111072A9
Authority
WO
WIPO (PCT)
Prior art keywords
ezh2
shrna
aav
adeno
therapy
Prior art date
Application number
PCT/IN2011/000161
Other languages
French (fr)
Other versions
WO2011111072A2 (en
Inventor
Koteswara Rao Kollipara
Original Assignee
Transgene Biotek Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Biotek Ltd. filed Critical Transgene Biotek Ltd.
Publication of WO2011111072A2 publication Critical patent/WO2011111072A2/en
Publication of WO2011111072A9 publication Critical patent/WO2011111072A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
PCT/IN2011/000161 2010-03-10 2011-03-10 Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer WO2011111072A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN331/CHE/2010 2010-03-10
IN331CH2010 2010-03-10

Publications (2)

Publication Number Publication Date
WO2011111072A2 WO2011111072A2 (en) 2011-09-15
WO2011111072A9 true WO2011111072A9 (en) 2011-11-03

Family

ID=44563943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000161 WO2011111072A2 (en) 2010-03-10 2011-03-10 Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer

Country Status (1)

Country Link
WO (1) WO2011111072A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140162319A2 (en) * 2012-05-02 2014-06-12 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
CN105307683A (en) 2013-03-14 2016-02-03 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
EP3997214B1 (en) * 2019-07-11 2023-08-02 Centre National de la Recherche Scientifique Chemically-modified adeno-associated virus

Also Published As

Publication number Publication date
WO2011111072A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
IL258740B (en) Combinational lipsosome compositions for cancer therapy
EP2542583B8 (en) Methods for treating breast cancer
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
EP2785743A4 (en) Anti-ceacam1 recombinant antibodies for cancer therapy
EP2752198A4 (en) Vaccine preparation for cancer treatment
WO2012006032A9 (en) Treatment of blood cancer
HK1217093A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2617413A4 (en) Nano-vehicle derived from tumor tissue, and cancer vaccine using same
HK1208804A1 (en) Tumor tissue based biomarkers for bevacizumab combination therapies
HRP20181757T1 (en) Combination therapy for treating breast cancer
HK1185874A1 (en) Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer 4--n--
ZA201300762B (en) Novel combination therapy for the treatment of cancer
WO2012018877A9 (en) Treating breast cancer with anti-il-19 antibody
EP2585115A4 (en) Cancer therapy
WO2011111072A9 (en) Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
GB201106630D0 (en) Cancer therapy
WO2012106461A9 (en) Combination therapy for treatment of cancer
AU2010905198A0 (en) Cancer therapy
EP2750691A4 (en) Srpx for treatment of cancer
AU2012905667A0 (en) Vaccines for treatment of cancer
AU2010904590A0 (en) Treatment Therapy
AU2012904570A0 (en) Cancer therapy using miRNAs
AU2010904107A0 (en) Treatment of cancer
GB201118220D0 (en) Cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11752950

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11752950

Country of ref document: EP

Kind code of ref document: A2